高血压患者血浆肾素-血管紧张素-醛固酮系统活性水平与降压效果的关系

陈海荣; 潘碧云; 李名兰; 温达; 陆士娟

doi:10.13201/j.issn.1001-1439.2017.09.015

高血压患者血浆肾素-血管紧张素-醛固酮系统活性水平与降压效果的关系

- 海口市人民医院心内科(海口, 570208)

详细信息

通讯作者: 陆士娟, E-mail:huadu34525@163.com

中图分类号: R544.1

收稿日期: 2017-02-17

修回日期: 2017-05-15

Relationship between plasma renin-angiotensin-aldosterone system activity and antihypertensive effects in patients with essential hypertension

- Department of Cardiology, Haikou People's Hospital of Hainan, Haikou, 570208, China

More Information

Corresponding author: LU Shijuan, E-mail: huadu34525@163.com

Received Date: 17 February 2017

Revised Date: 15 May 2017

摘要

摘要: 目的:探讨高血压患者血浆肾素-血管紧张素-醛固酮系统(RAAS)活性水平与降压效果的关系。方法:选取2014-12-2016-12我院心内科收治的原发性高血压患者400例,按研究需要分为血浆肾素活性(PRA)升高组与PRA不高组、血管紧张素Ⅱ(AngⅡ)升高组与AngⅡ不高组、醛固酮(ALD)升高组与ALD不高组,分析各对组间的临床参数;并按年龄分为低龄组与高龄组,分析2组间的RAAS水平,比较不同RAAS等级患者药物治疗的情况。结果:除年龄外,其他的临床参数均与PRA、AngⅡ、ALD无关(P>0.05);低龄组患者的PRA、AngⅡ和ALD均显著高于高龄组(P<0.05);随着RAAS等级的升高,血管紧张素转换酶抑制剂(ACEI)和血管紧张素Ⅱ受体拮抗剂(ARB)、ALD拮抗剂的使用随之增加(P<0.05),而利尿剂、钙拮抗体(CCB)的使用随之减少,差异有统计学意义(P<0.05);出院时,不同等级之间的血压达标率均较理想,无明显差异(P>0.05)。结论:低龄高血压患者的RAAS活性相对较高,根据RAAS活性的检测结果选择降压方案,可以获得理想的血压达标率。
- 高血压 /
- 肾素-血管紧张素-醛固酮系统 /
- 降压效果
Abstract: Objective:To investigate the relationship between plasma renin-angiotensin-aldosterone system activites and antihypertensive effects in patients with essential hypertension.Method:Four hundred patients with essential hypertension admitted from December, 2014 to December, 2016, were divided into several groups according to research need.We compared the clinical parameters between PRA elevated group and PRA not high group, between Ang Ⅱ elevated group and AngⅡ not high, as well as between ALD elevated group and ALD low group.The drug therapies were also compared among different RAAS grades.Result:Except for age (P<0.05), other clinical parameters were not related to the level of PRA, AngⅡ and ALD (P>0.05).PRA, Ang Ⅱ and ALD in the younger age group were significantly higher than those in the older age group (P<0.05).The use of ACEI/ARB and aldosterone antagonists were increased with the higher level of RAAS (P<0.05), however the use of diuretic and CCB were decreased (P<0.05).There was no significant difference in the compliance rate of blood pressure between different grades at discharge (P>0.05). Conclusion:The RAAS activities of young patients with hypertension is relatively high and we can choose the anti-hypertension program and get the ideal blood pressure target on the basis of the detected RAAS activities.
- hypertension /
- renin-angiotensin-aldosterone system /
- antihypertensive effect

HTML全文

参考文献(17)

[1]	BLACHER J, LEVY B I, MOURAD J J, et al.From epidemiological transition to modern cardiovascular epidemiology:hypertension in the 21st century[J].Lancet, 2016, 388:530-532.
[2]	MOON J Y.Recent Update of Renin-angiotensin-aldosterone System in the Pathogenesis of Hypertension[J].Electrolyte Blood Press, 2013, 11:41-45.
[3]	ZAIN M, AWAN F R.Renin Angiotensin Aldosterone System (RAAS):its biology and drug targets for treating diabetic nephropathy[J].Pak J Pharm Sci, 2014, 27:1379-1391.
[4]	李云, 杨鹏, 武英, 等.原发性高血压患者肾素-血管紧张素-醛固酮系统活性与空腹血糖水平的关系[J].中国糖尿病杂志, 2014, 22 (2):135-137.
[5]	孙宁玲.难治性高血压的治疗进展[J].中国医学前沿杂志 (电子版), 2013, 5 (6):1-4.
[6]	史载祥.对《中国高血压防治指南2010》的质疑与建议[J].中医杂志, 2016, 57 (11):986-987.
[7]	林凡礼, 战义强, 贾贡献, 等.中国门诊高血压患者血压达标现状及影响因素分析[J].中华高血压杂志, 2013, 21 (2):170-174.
[8]	MOON J Y.Recent Update of Renin-angiotensin-aldosterone System in the Pathogenesis of Hypertension[J].Electrolyte Blood Press, 2013, 11:41-45.
[9]	TE RIET L, VAN ESCH J H, ROKS A J, et al.Hypertension:renin-angiotensin-aldosterone system alterations[J].Circ Res, 2015, 116:960-975.
[10]	李玉明, 杨宁.盐敏感性高血压特点及防治[J].中国实用内科杂志, 2015, 35 (4):299-302.
[11]	文佳, 李莹, 袁洪.关注夜间高血压影响因素, 选择合理治疗方案[J].中国全科医学, 2015, 18 (8):860-864.
[12]	CABANDUGAMA P K, GARDNER M J, SOWERS J R.The Renin Angiotensin Aldosterone System in Obesity and Hypertension:Roles in the Cardiorenal Metabolic Syndrome[J].Med Clin North Am, 2017, 101:129-137.
[13]	BHULLAR K S, LASSALLE-CLAUX G, TOUAIBIA M, et al.Antihypertensive effect of caffeic acid and its analogs through dual renin-angiotensin-aldosterone system inhibition[J].Eur J Pharmacol, 2014, 730:125-132.
[14]	SEALEY J E, ALDERMAN M H, FURBERG C D, et al.Renin-angiotensin system blockers may create more risk than reward for sodium-depleted cardiovascular patients with high plasma renin levels[J].Am J Hypertens, 2013, 26:727-738.
[15]	孙宁玲, 霍勇, 王继光, 等.难治性高血压诊断治疗中国专家共识[J].中华高血压杂志, 2013, 21 (4):321-326.
[16]	陈伟伟, 高润霖, 刘力生, 等.中国心血管病报告2013概要[J].中国循环杂志, 2014, 29 (7):487-491.
[17]	张梅, 李玉明.高血压合理用药指南解读——高血压特殊并发症药物治疗原则[J].中国医学前沿杂志 (电子版), 2016, 8 (2):6-9.